10-K: Cadrenal Therapeutics Reports 2024 Annual Results and Provides Business Update

Cadrenal Therapeutics' 2024 annual report highlights the company's focus on developing tecarfarin for rare cardiovascular conditions and its recent collaboration with Abbott.

Summary

• Cadrenal Therapeutics is focused on developing tecarfarin, a novel oral anticoagulant, for unmet needs in rare cardiovascular conditions.
• The company is targeting conditions like LVADs, ESKD with AFib, and catastrophic APS, where current anticoagulation therapies have limitations.
• A collaboration agreement was established with Abbott in March 2025 to support the Phase 3 TECH-LVAD study evaluating tecarfarin in LVAD patients.
• The FDA has indicated support for a non-inferiority trial design with a composite clinical endpoint for the TECH-LVAD study.
• Tecarfarin has received Orphan Drug Designation for prevention of thromboembolism in ESKD patients with AFib and in patients with implanted mechanical circulatory support devices.
• The company plans to initiate a pivotal Phase 3 clinical trial in late 2025 or early 2026, contingent on additional financing.
• Cadrenal intends to expand its product pipeline through partnerships, in-licensing, or acquisitions of clinical-stage cardiovascular products.
• The company aims to build a commercial infrastructure for its product candidates, including a specialty salesforce targeting top prescribing physicians and anticoagulation clinics.
• Tecarfarin has been evaluated in 11 human clinical trials involving over 1,000 individuals.
• The company incurred operating expenses of $10.96 million in 2024, compared to $7.63 million in 2023.
• The net loss for 2024 was $10.65 million, compared to $8.36 million in 2023.
• As of March 13, 2025, the company had cash and cash equivalents of approximately $7.9 million.
• The company will need to raise additional capital to fund its planned Phase 3 clinical trial.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments such as the Abbott collaboration and FDA feedback, the company's financial position and the need for additional funding create uncertainty.

Positives

• Collaboration with Abbott provides access to data and expertise for the TECH-LVAD trial.
• FDA input supports a potential path forward for regulatory approval.
• Orphan Drug Designation provides benefits such as marketing exclusivity and user fee waivers.
• Focus on rare cardiovascular conditions with unmet needs offers a targeted market opportunity.
• Prior clinical trials have shown tecarfarin to be generally well-tolerated.

Negatives

• The company has a limited operating history and a history of losses.
• Additional capital is needed to fund the planned Phase 3 clinical trial.
• The success of the company is heavily dependent on the success of tecarfarin.
• The company faces substantial competition from established pharmaceutical companies.
• The company's U.S. patents for tecarfarin expired in April 2024, and foreign patents will expire in April 2025.

Risks

• The company may not be able to obtain regulatory approval for tecarfarin.
• Clinical trials are expensive and time-consuming, and delays may occur.
• The company may not be able to commercialize tecarfarin successfully.
• The company relies on third-party manufacturers and may face supply chain disruptions.
• The company may be subject to product liability lawsuits.
• The company is increasingly dependent on information technology, and its systems face certain risks, including cybersecurity threats.

Future Outlook

The company plans to initiate a pivotal Phase 3 clinical trial in late 2025 or early 2026, contingent on additional financing, and expand its product pipeline through partnerships or acquisitions.

Management Comments

• Management intends to raise additional funds through partnering and equity and debt financings.

Industry Context

The report acknowledges the challenges in cardiovascular drug development due to high costs and regulatory demands, while also highlighting the unmet needs in specific patient populations where existing anticoagulation therapies have limitations.

Comparison to Industry Standards

• The report mentions warfarin and DOACs (Eliquis, Xarelto, Pradaxa, Savaysa) as existing anticoagulant treatments.
• It notes that warfarin often fails to achieve the benchmark TTR of 70% in optimally controlled clinical trials.
• The ARIES-HM3 study showed an average TTR of only 56% with warfarin in LVAD patients.
• The EMBRACE-AC study showed that tecarfarin TTR was significantly better than warfarin in patients at higher risk for CYP450 issues.

Management Changes

Stakeholder Impact

• Shareholders: Dilution may occur from future equity financings.
• Employees: Potential for growth and development with company expansion.
• Patients: Potential for new treatment options for rare cardiovascular conditions.

Next Steps

• Initiate a pivotal Phase 3 clinical trial in late 2025 or early 2026, subject to funding.
• Seek to expand the label for tecarfarin through a supplemental NDA.
• Partner and/or in-license and/or acquire clinical-stage cardiovascular products.
• Create a commercial infrastructure for product candidates.

Key Dates